Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

£30M clinical study will enhance the understanding of NASH cirrhosis

The most extensive clinical study into liver cirrhosis ever conducted worldwide has been announced by Newcastle University, University of Edinburgh and leading research-driven global biopharmaceutical

January 9, 2024

Remote manufacturing assessments: FDA revises draft guidance to include newly expanded powers

The FDA on Friday released newly revised Q&A guidance on how the agency can use voluntary and mandatory remote regulatory assessments to better understand biopharma

January 27, 2024

Generic drug lobby taps former BIO exec as new CEO

WASHINGTON — The trade association for generic drugs and biosimilars has chosen a new leader: John Murphy. Four sources familiar with the decision said Murphy

September 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.